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Running head: Pedometer step count targets during PR in COPD 
 
Impact of this research:  
This trial contributes high-quality evidence against the routine use of pedometers and step 
targets during pulmonary rehabilitation (PR) to improve physical activity levels, or enhance 
the established benefits of PR on exercise capacity and health-related quality of life in COPD 
in the short to medium term. It also demonstrates that pedometers may limit the positive 
benefits of PR on some aspects of quality of life in the short term, reflecting the added burden 
of wearing a pedometer on a daily basis. Considering this trial with other literature, current 
available evidence suggests that pedometers confer the most benefit to people with COPD 
when used outside of PR.  
 
Descriptor number: 9.37: Pulmonary Rehabilitation 
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At a glance:  
Scientific knowledge on the subject: Despite the strong evidence base for pulmonary 
rehabilitation (PR) in improving exercise capacity in people with COPD, the effect on 
physical activity levels is uncertain. To date, three small, randomized controlled trials have 
examined the effect of pedometers on patients with COPD undergoing PR, with conflicting 
results (1-3). Methodologies and intervention strategies were varied, and studies 
underpowered, with high risk of effect size error and sample bias.  
 
What this study adds to the field: This trial contributes high-quality evidence demonstrating 
that the routine use of pedometer feedback and step targets does not augment the effects of 
PR on physical activity levels, exercise capacity or health-related quality of life in patients 
with COPD. Pedometers might limit the effect of PR on some aspects of quality of life in the 
short term,  reflecting the added burden of using the pedometer on a daily basis. 
This article has an online data supplement, which is accessible from this issue's table of 
content online at www.atsjournals.org
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ABSTRACT  
Rationale: Increasing physical activity is a key therapeutic aim in COPD. Pulmonary 
rehabilitation (PR) improves exercise capacity, but there is conflicting evidence regarding its 
ability to improve physical activity levels.  
Objective: To determine whether using pedometers as an adjunct to PR can enhance time 
spent in at least moderate intensity physical activity (time ≥ 3METs) in people with COPD. 
Methods: In this single-blinded randomized controlled trial, participants were assigned 1:1 to 
receive control (PR comprising 8 weeks, two supervised sessions/week) or intervention (PR 
plus pedometer-directed step targets, reviewed weekly for 8 weeks). The randomisation 
process used minimisation to balance groups for age, sex, FEV1 % predicted, and baseline 
exercise capacity and physical activity levels. Outcome assessors and PR therapists were 
blinded to group allocation. The primary analysis was by intention-to-treat and the trial 
registered with clinicaltrials.gov (Ref. NCT01719822). 
Measurements: The primary outcome was change from baseline to 8 weeks in 
accelerometer-measured daily time ≥3METs.   
Main results: 152 participants (72% male; mean (SD) FEV1 % predicted 50.5 (21.2); median 
(Q1, Q3) time ≥3METS 46 (21, 92) minutes) were enrolled to intervention (n=76) or control 
(n=76).  There was no significant difference in change in time ≥3METs between the 
intervention and control groups at 8 weeks (median (Q1, Q3) difference 0.5 (-1.0, 31.0) 
minutes; p=0.87) or at the 6 month follow-up (7.0 (-9, 27) minutes; p=0.16). 
Conclusion: Pedometer-directed step count targets during an outpatient PR program did not 
enhance moderate intensity physical activity levels in people with COPD. 
Word count: 245   
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INTRODUCTION  
Increasing physical activity levels is a key therapeutic aim in chronic obstructive pulmonary 
disease (COPD) (4) because physical inactivity is associated with increased risk of mortality 
and exacerbations, greater decline in lung function, and impaired quality of life (5-7). There 
is strong evidence for the effectiveness of pulmonary rehabilitation (PR) on exercise capacity 
in COPD (8), but the effect of PR on physical activity levels is modest (9). 
Pedometers may help people to become more active. A meta-analysis of 18 observational 
studies and 8 randomized controlled trials involving 2,767 outpatients found pedometer use 
was associated with a significant increase in physical activity levels (10). In a recent single-
centre randomized controlled trial among stable COPD patients, a pedometer-based physical 
activity program led to significantly greater improvement in physical activity levels, exercise 
capacity and quality of life, when compared to simple encouragement to be more active (11). 
In contrast, Burtin and colleagues showed that the addition of simple physical activity 
counselling alone did not enhance the effects of PR on physical activity levels ( (12). 
We postulated that pedometers could enhance the effects of PR on physical activity levels. To 
date, three small, randomized controlled trials have explored the effect of pedometers as an 
adjunct to PR (1-3). The results were conflicting, reflecting intervention heterogeneity and 
trial methodologies. The trials were also underpowered (n=16 to 39), and at high risk of 
effect size error and sample bias (1-3).  
The aim of this trial was to determine the short- and medium-term effectiveness of 
pedometer-directed step targets, as an adjunct to outpatient PR, on physical activity levels, 
exercise capacity and health-related quality of life in people with stable symptomatic COPD. 
We hypothesized that the use of pedometers would enhance the short- and medium- term 
effects of PR on physical activity levels, exercise capacity and health-related quality of life. 
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METHODS 
Trial design and participants 
We conducted a parallel, two-group, assessor-blinded, randomized controlled trial 
investigating the effect of a pedometer intervention during and following PR on physical 
activity levels in people with COPD. Recruitment took place within the Harefield Hospital 
PR Unit, UK, between July 2012 and June 2014, from patients undergoing an initial PR 
assessment. Eligible participants were ≥35 years of age with a physician diagnosis of COPD 
consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria 
(13), with MRC dyspnea scale ≥2, who consented to supervised PR. Exclusion criteria 
included contraindication to exercise (e.g. significant cardiovascular co-morbidities), or 
participants choosing a community PR site without access to specialist exercise equipment. 
All participants provided written informed consent. The trial protocol was pre-registered with 
clinicaltrials.gov (Ref. NCT01719822) and approved by the West London Research Ethics 
Committee (Ref. 11/LO/1021). 
 
Randomization and blinding 
Following baseline assessment, participants were randomly allocated (1:1) to receive usual 
care or usual care plus the pedometer intervention. The allocation sequence was computer-
generated (Minim), accessed by a researcher independent of the recruitment process, PR 
program provision, trial intervention, and outcome assessment. Minimisation was used to 
balance groups for age (≤/> 65 years), sex (male/female), GOLD stage (I-II/III-IV), 
Incremental Shuttle Walk Test (ISWT) distance (</≥170m), oxygen use (yes/no), and, 
Physical Activity Level (PAL </≥1.4) (14). It was not possible to conceal group allocation 
from participants. Subsequent assessment visits were completed immediately after the PR 
program (8 weeks) and 6 months following the end of the PR program by assessors blinded to 
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group allocation. The statistician undertaking the primary statistical analysis (WB) was 
blinded to group allocation. 
 
Intervention 
Usual care was a standardized twice weekly supervised, 8-week outpatient PR program (see 
online supplement).  The additional intervention was provision of a pedometer (Yamax 
Digiwalker CW700®, Yamax, Nottingham, UK), an individualised daily pedometer step 
count target (with weekly review for 8 weeks), and a step count diary provided during the PR 
program and the following 6 months. During PR, the daily pedometer step count target was 
an increase of 5% on the preceding week’s average daily pedometer step count, with the first 
week’s target derived from the baseline pre-PR assessment (e.g. 250 additional steps from a 
mean daily step count of 5,000). At this weekly step count review, each patient was 
counselled on the importance of achieving the pedometer step count and given advice on how 
to increase physical activity levels, focusing on barriers and opportunities arising during daily 
life. On completion of the PR program, participants in the intervention group received a final 
step count target based on a 20% increase in daily step count from the baseline pre-PR 
assessment and a step count diary. The detailed intervention protocol is described in the 
online supplement.  
 
Outcomes 
Participants wore an accelerometer (SenseWear®, Body Media Inc, Pittsburgh, USA) and 
pedometer for 7 days at the baseline, immediate post-PR, and 6 month follow-up assessment 
visits.  Data recorded by the accelerometer included mean daily step count and time spent 
performing moderate intensity physical activity (time ≥3 METs) (7, 15, 16). The pedometer 
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measured daily step count and participants noted this number in the trial diary.  Further 
information on the accelerometer and pedometer are in the online supplement. 
Additional assessments included spirometry, functional exercise capacity using the ISWT 
(17) and health status with the Chronic Respiratory Questionnaire (CRQ). To gather feedback 
on pedometer usage, participants allocated to the intervention completed a telephone survey 
after the 6-month assessment; questions concerned positive and negative attributes of using 
the pedometer, physical activity undertaken after the study, and ideas that might motivate 
participants to exercise. 
The primary outcome was change in daily time spent in at least moderate intensity physical 
activity (time ≥3 METs) from baseline to immediately following PR. Secondary outcomes 
were change in time ≥3 METs at 6 months following PR, and change in accelerometer and 
pedometer step counts, ISWT, CRQ domains and total score. Adverse events, hospitalizations 
and deaths were recorded throughout the trial. 
 
Statistical analysis 
Our sample size was based on a previous study, which demonstrated that a 3-month PR 
program increased the average daily walking time assessed using an accelerometer by a mean 
(SD) of 7 (35)% (18). We assumed an additional increase in moderate intensity physical 
activity of 20% would represent a clinically relevant improvement. To detect this using a two 
sample t-test with 80% power at the 0.05 significance level (two-sided), assuming equal 
variances, 50 participants per group were required. Based on PR studies of similar duration, 
we allowed for attrition during PR (22%) and from PR to 6 months post-PR (33%), and 
planned to recruit 155 participants overall. 
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Data were exported from a Microsoft® Office Access® 2010 database (Microsoft® 
Washington, USA) and analysis was completed by the trial statistician (WB) using Stata 14.1 
(StataCorp LP, Texas, USA). The pre-specified primary analysis was by intention to treat. 
Missing data were explored and reported according to cause (19). Missing data were handled 
by a Markov Chain Monte Carlo method, using multiple imputations (10 datasets).. Data 
were assumed to be from a multivariate normal and data augmentation was applied to 
Bayesian inference with missing data. The data were log transformed for multiple imputation 
and then anti-logged. 
Continuous data were expressed as mean with SD or 95% confidence intervals, and compared 
between groups with unpaired Student’s t test (20). Non-normally distributed data were 
expressed as median (Q1, Q3) and compared between groups with Mann-Whitney U test 
(20). Categorical data were presented as percentages, and compared between groups with 
Pearson X
2
 test (20). Outcomes were summarized as change from baseline. We used 
independent samples Student’s t test (two-sided) or Mann Whitney U test to compare change 
in time ≥3 METs physical activity (primary outcome) and secondary outcomes immediately 
and 6 months following PR, by trial group (20). Sensitivity analysis considered complete-
cases only, i.e. with paired observations, to account for possible impact of data imputation 
(online supplement: Table 1), and participants not achieving ≥150 minutes of moderate 
intensity physical activity each week at baseline (Table 3). A p-value <0.05 indicated 
statistical significance. Telephone survey data were handled using Microsoft® Office Excel® 
2010 database (Microsoft®, Washington, USA) and content analysis was used to explore 
participants’ experience of the intervention. We identified categories inductively from the 
interview data, with attention to terms and content.  
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RESULTS 
Patient Flow 
Figure 1 shows the CONSORT flowchart.  In total, 155 people were consented with 152 
randomized. Baseline characteristics are shown in Table 1. (21) 
Outcomes were obtained for 122 (80.3%) and 113 (74.3%) participants at the immediate 
post-PR and 6-month follow-up assessments respectively, with similar attrition rates across 
groups (Figure 1). The planned intervention offered eight opportunities (each week of PR) for 
a new step count target to be set using 5% increments. In the intervention group, participants 
did not increase their target by 5% on a mean (SD) 5 (1) occasions during PR, because 
participants missed their PR session, could not be contacted by phone, or the previous weeks 
target was not met. 
Valid accelerometer data for the primary outcome measure were available in 92 participants 
at the immediate post-PR assessment (intervention: n=46; control: n=46), and 93 participants 
at the 6-month follow-up assessment (intervention: n=44; control: n=49). The reasons for 
missing accelerometer data in the online supplement: Table 1. Missing data and dropouts 
were not associated with baseline age, sex, FEV1 %predicted, exercise capacity, CRQ scores, 
or group allocation, and were considered missing at random. Consequently, multiple 
imputation was performed for the primary outcome, and analyzes involved all randomly 
assigned participants. 
 
Primary Outcome 
Table 2 and Figure 2 show change in time ≥3 METs from baseline to 8 weeks, and from 
baseline to 6 months following PR program. We found no significant between group 
difference in time ≥3 METs from baseline to 8 weeks (median (Q1, Q3) change: intervention 
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11 (-1, 33) minutes versus control 11 (-2, 28) minutes; p=0.62). Similarly, no significant 
between group difference in change in time ≥3 METs were observed at 6 months 
(intervention: 2 (-12, 25) minutes versus control: 12 (-7, 31) minutes; p=0.16) (Table 2 and 
Figure 2). This finding was consistent when only complete-cases were considered (online 
supplement 1: Table 2). 
 
Secondary Outcomes 
Figure 3 shows the overall progression in daily pedometer step count achieved during PR in 
the intervention group. The median (Q1, Q3) step count target for the final week of PR was 
36 (0, 76)% higher than participants’ baseline step count.   
Consistent with the findings for the primary outcome measure, there were no significant 
between-group differences for accelerometer-recorded step count, pedometer-recorded step 
count, or ISWT at either time point (Table 2). At all time-points, the median accelerometer-
recorded daily step count was greater than the pedometer-recorded step count, the 
discrepancy potentially arising from the poor accuracy of pedometers at slow walking speeds 
(21). 
Unexpectedly, short-term improvements in CRQ scores following PR were significantly 
greater in the control group, as compared to the intervention group, for the fatigue (p<0.01) 
and mastery (p=0.047) domains as well as the total score (p<0.01). We also adjusted for 
baseline CRQ values and the group effect for differences in the fatigue domain and total 
score remained significant (online supplement:  Table 3). However, between-group 
differences in CRQ did not persist at 6 months. 
Given recent insights suggesting the effects of adjunct interventions during PR depend on 
them being offered in a targeted manner (22), we undertook a post-hoc sensitivity analysis 
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only considering  the 38/152 (25%) participants with low baseline physical activity levels 
(≤150 minutes of moderate intensity physical activity each week), as per international 
guidelines (23, 24). The finding for the primary outcome did not change at 8 weeks (median 
(Q1, Q3) change 10 (2, 18) vs. 10 (6, 15) minutes, p=0.20) nor at the 6 month follow up (2 (-
1, 25) vs. 14 (5, 31) minutes, p=0.52) (Table 3). There were no longer significant differences 
in CRQ scores following PR, suggesting the pedometer intervention blunts CRQ response to 
PR principally in those with higher levels of physical activity at trial entry (Table 3). Data for 
patients achieving ≥150minutes of moderate intensity physical activity per week is presented 
in the online supplement: Table 4. 
The survey feedback on the pedometer was mixed. Some participants felt positive about the 
intervention, “it was interesting to get feedback…good to push myself” and that it provided 
“an incentive to go walking”, whilst other reported issues with its use, e.g. “it needed to be 
clipped onto a waistband and so it was impossible to wear a dress” or “it didn’t pick up all of 
my steps”. Others revealed they could “alter it (the step count) by shaking it”. Some 
participants reported that they stopped using the pedometer following PR due to a change in 
clinical condition, such as after an exacerbation “I had a really bad chest infection…as I 
couldn’t leave the house, I didn’t see the point in wearing it”, or perception of its role “I 
stopped because I became obsessed with the step count target”. On completion of PR, 
participants reported that physical activity levels tended to decline due to lack of incentive to 
exercise or becoming unwell with a chest infection.  
The proportion of participants experiencing adverse events during and following PR was 
similar between groups. One participant experienced an allergic reaction to the nickel 
baseplate of the accelerometer during baseline assessments, and as a result, was not 
randomized. In total, there were 56 hospital admissions (intervention 23; control 33 ; p=0.50). 
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Thirty of these admissions were for COPD (intervention 14; control 16 ; p=0.29). Four deaths 
(two in each group) were recorded during the study period. 
 
DISCUSSION 
Contrary to our hypothesis, this single-blind randomized controlled trial demonstrated that 
pedometer-directed step count targets did not enhance the short- or medium-term effects of 
PR on moderate intensity physical activity levels, daily step-count, exercise capacity, or 
health-related quality of life in people with COPD. Indeed, there was evidence that the 
intervention was associated with a reduced improvement in some aspects of health-related 
quality of life with PR , though this difference did not persist at 6 months. 
To our knowledge, two previous trials (1, 3) and a sub-study of a larger trial (2) have 
examined the use of pedometers as an adjunct to PR. Findings have been conflicting, which 
may reflect intervention heterogeneity and small sample sizes. Our study bears similarities to 
that described by Kawagoshi and colleagues (3). Pedometer feedback was the main 
intervention, whilst an accelerometer was used to objectively measure physical activity 
levels. There was limited physical activity counselling other than simple monthly verbal 
reinforcement to increase physical activity. Unlike our study, the authors were able to 
demonstrate a significant between-group difference in walking time in favour of the 
intervention group at 1 year (3). However, only 27 patients completed the study with no 
attempt to impute missing data, and the PR program was home-based, low intensity and 
minimally supervised. In the study by de Blok and colleagues the intervention consisted 
primarily of four individual exercise-counselling sessions, with pedometers used as 
motivational and feedback tools (1). This study was very underpowered (only 16 patients in 
total completed), and the randomization process was not well described. Although both 
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intervention and control groups showed a significant increase in daily step count, there were 
no statistically significant between group differences (1). In a larger trial, Altenburg and 
colleagues also studied the effects of a lifestyle physical activity counselling program in 
stable COPD outpatients (2). The intervention included pedometers used as motivational and 
feedback tools. In a subgroup analysis of patients undergoing PR, the authors demonstrated a 
short-term additive improvement in daily step count with the intervention, but this did not 
persist at 15 months (2). There were marked differences between their study and ours. First, 
the Altenburg study cohort was considerably younger (mean age 54 years versus 68 years) 
with more severe airways obstruction (mean FEV1 43% versus 50%). Second, the PR sub-
study population was considerably smaller with only 37 and 23 patients providing data at 3 
months and 15 months respectively with no attempt to impute missing data. Third, the 
primary outcome in the Altenburg study was pedometer step count, which has significant 
limitations; our choice of multisensory accelerometer is considered a more accurate measure 
of physical activity. Finally, there were differences in baseline physical activity parameters 
between the control and intervention groups of the PR sub-study. This was not corrected for 
in the between group difference analysis. 
Four randomized controlled trials and two uncontrolled interventional studies outside of PR, 
using pedometers and either a physical activity counselling program (2, 11, 25) or an internet-
mediated pedometer-based program (26-28), have generally been positive by showing 
improvements in daily pedometer step count. A number of possibilities may account for the 
difference in physical activity outcomes between our study and these studies. Our study used 
an accelerometer to assess the impact of the intervention on physical activity, whereas the 
aforementioned studies employed pedometers. The capacity of pedometers to reliably 
measure physical activity is disputed owing to inconsistent construct and convergent validity 
and reliability at slow walking speeds, as well as the ability to manipulate the step count by 
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shaking the device (21, 29-32). Three of the studies (25, 27, 28) were small (range 24 to 35 
participants) and only two studies provided a sample size calculation (2, 11). The contact 
time with healthcare professionals was greater in the aforementioned studies with time-
periods ranging from 12 to 52 weeks (25, 26) in contrast to 8 weeks in our study. 
Furthermore, only one study in addition to ours assessed the medium-term impact of the 
intervention on physical activity levels (33). 
There were a number of important secondary findings in this study. The use of a pedometer 
appeared to blunt the effects of PR on some health-related quality of life domains.  This may 
reflect the added burden of using a pedometer and step count diary as evidenced by some 
negative feedback in the qualitative interviews. The reduction in pedometer step count from 
week 8 of PR program to post-PR assessment is noteworthy as it suggests that participants 
rapidly became more sedentary on stopping PR. This was further compounded by the 
consistent drop in physical activity levels from immediately to 6 months post-PR in both 
groups, which may indicate that an 8-week outpatient PR program is insufficient to elicit 
long-term behaviour change (34).  
Strengths of our study include the use of randomization and an intention to treat analysis to 
limit risk of bias, and an adequate sample size to test our a priori hypothesis. Our study is the 
largest trial to explore the adjunct use of pedometers during PR. Outcome assessors and PR 
staff were blinded to group allocation, and, although due to the nature of the intervention it 
was not possible to do this with the trial participants, the primary outcome of objective, 
accelerometer-recorded physical activity parameters partly mitigates this source of bias (35). 
Importantly, this data was measured independently of the intervention device. Our 
assessment of outcomes immediately and 6 months following PR was rigorous, allowing us 
to examine both short- and medium- term effects of the intervention. 
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There are limitations to consider.  Our a priori sample size calculation required 50 subjects in 
both the intervention and control groups to complete at the immediate post-PR time-point.  
There was unexpectedly high invalid or missing data from the accelerometer, and primary 
outcome measure data was available in only 46 pedometer and 46 control subjects, so the 
study may be underpowered. However, imputation of accelerometer data partly mitigated 
this. In addition, there was a wide variability in physical activity levels as measured using the 
accelerometer.  A number of different methods analysing physical activity data exist. At the 
time of study planning, we pre-specified the then recommended method by Watz and 
colleagues(7), which involves analysing 5 days of data: 3 weekdays and 2 weekend days. 
However recent data from Demeyer and colleagues (36) recommend analysing 4 weekdays 
with ≥8hours data and considering daylight time to help reduce variability. With hindsight, a 
greater focus on the behavioural aspects may have produced more positive results in our trial 
but we note a recent trial from Burtin et al (12) which used a comprehensive physical activity 
behavioural program (eight individual activity counselling sessions without pedometer 
feedback) alongside PR as their intervention. Like our study, this failed to show an additional 
benefit on physical activity levels compared with PR  alone. In the PR setting, de Blok and 
colleagues also failed to augment the benefits of PR with a combined approach of physical 
activity counselling with pedometer feedback (1). However, our intention was to design an 
intervention that was pragmatic and feasible to implement easily into a standard PR program 
without significant increase in staff time, and that would encourage patient self-management.  
 
Conclusion 
The study findings indicate that pedometer-directed step targets do not enhance the effects of 
PR on short- or medium-term physical activity levels, exercise capacity or health-related 
quality of life. These data do not support the routine use of pedometers to augment physical 
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activity during PR programs. In light of this, studies investigating alternative methods to 
enhance physical activity are necessary in order to realise the physical activity-associated 
health and economic benefits in people with COPD attending PR.  
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FIGURE LEGENDS 
FIGURE 1: CONSORT diagram. 
 
FIGURE 2:  Progression of daily pedometer step count targets during pulmonary 
rehabilitation among participants allocated to the pedometer intervention. 
 
FIGURE 3: Daily time spent ≥3 METs before, after and 6 months following PR in the control 
and intervention groups. 
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TABLES 
TABLE 1. Baseline characteristics 
 
Data are mean (SD) or median [Q1, Q3] unless stated otherwise. FEV1: Forced Expiratory 
Volume in 1 second; FVC: Forced Vital Capacity; MRC: Medical Respiratory Council 
Dyspnea Scale; ADO Index: Age Disability Obstruction Index; COTE Index: COPD Specific 
Co-morbidity Index; 4MGS: 4 Meter Gait Speed; ISWT: Incremental Shuttle Walk Test; 
CRQ: Chronic Respiratory Questionnaire; METs: Metabolic Equivalents
Variable 
 
Whole group 
(n=152) 
 
Intervention group 
(n= 76) 
 
Control group 
(n=76) 
Sex (male) (number (%)) 110 (72) 56 (74) 54 (71) 
Age (years) 68 (9) 69 (9) 68 (8) 
FEV1 (% predicted) 50.5 (21.2) 50.6 (20.7) 50.3 (21.8) 
FEV1/FVC 0.50 (0.15) 0.51 (0.15) 0.50 (0.16) 
MRC score 3 (1) 3 (1) 3 (1) 
Smoking status  
Never, number (%) 2 (1.3) 1 (1.3) 1 (1.3) 
Former, number (%) 123 (80.9) 63 (82.9) 60 (79.0) 
Current, number (%) 27 (17.8) 12 (15.8) 15 (19.7) 
Pack-year history 40 (23, 60) 45 (34) 45 (29) 
ADO Index 4.6 (1.6) 4.7 (1.6) 4.6 (1.6) 
COTE Index 1 (0, 2) 1 (0, 3) 1 (0, 2) 
Sp02 on room air 95 (3) 95 (3) 96 (3) 
Current medication  
Long-acting bronchodilators 101 (66.4) 48 (63.2) 53 (69.7) 
Short-acting bronchodilators 120 (78.9) 61 (80.3) 59 (77.6) 
Inhaled corticosteroids 106 (69.7) 51 (67.1) 55 (72.4) 
Oral steroids (maintenance) 13 (8.6) 7 (9.2) 6 (7.9) 
Long-term oxygen therapy 4 (2.6) 1 (1.3) 3 (3.9) 
Ambulatory oxygen therapy 16 (10.6) 8 (10.5) 8 (10.5) 
Non-invasive ventilation 1 (0.7) 1 (1.3) 0 (0) 
BMI, kg/m
2
 28.1 (5.8) 28.7 (6.6) 27.6 (4.7) 
Walking aid  
None, number (%) 136 (89.5) 69 (90.8) 67 (88.2) 
Walking stick, number (%) 12 (7.9) 5 (6.6) 7 (9.2) 
Walking frame, number (%) 4 (2.6) 2 (2.6) 2 (2.6) 
4MGS, ms
-1
 0.96 (0.24) 0.96 (0.21) 0.96 (0.26) 
ISWT distance, meters 259 (145) 267 (156) 248 (138) 
CRQ  
Dyspnea 13.4 (5.7) 14.1 (6.3) 12.7 (4.9) 
Fatigue 13.9 (5.9) 14.6 (6.4) 13.1 (5.3) 
Emotion 31.4 (9.4) 33.5 (9.5) 29.3 (8.8) 
Mastery 18.2 (5.8) 19.2 (5.9) 17.1 (5.5) 
Total 76.8 (22.8) 81.4 (23.9) 72.2 (20.9) 
Accelerometer  
Moderate intensity physical      
activity (≥3 METs), min 
46 (19, 85) 45 (20, 81) 47 (18, 103) 
Daily accelerometer step count 3323 (1654, 5535) 3293 (1717, 5502) 3456 (1567, 5925) 
Daily pedometer step count 2418 (1440, 4261) 2329 (1416, 4449) 2531 (1440, 4062) 
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TABLE 2. Change in primary and secondary outcome measures in intervention and 
control groups 
 
 
Change baseline to  
immediately following PR  
p 
value 
Change baseline to  
6 months following PR  
p 
value 
 
Intervention 
 (n=63) 
Control  
(n=59) 
 
Intervention 
(n=56) 
Control  
(n=57) 
 
Primary outcome:   
Time spent ≥3 
METs 
(minutes/day) 
11 (-1, 33) 11 ( -2, 28) 0.62 2 (-12, 25) 12 (-7,  31) 0.16 
Secondary 
outcomes: 
Accelerometer step 
count (steps/day) 
272 (-342, 782) 155 (-438, 867) 0.99 -263 (-778, 197) -461 (-1168, -62) 0.09 
Pedometer step 
count (steps/day) 
727 (-1493, 3119) 892 (-1187, 2534) 0.55 116 (-1698, 3200) 481 (-1931, 1781) 0.85 
ISWT distance 
(meters) 
60 (20, 90) 50 (10, 90) 0.83 30 (0, 70) 10 (-30, 70) 0.25 
CRQ       
   Dyspnea 3.7 (2.1 to 5.2) 5.6 (4.2 to 7.0) 0.07 1.8 (-0.1 to 3.6) 3.7 (2.1 to 5.3) 0.10 
   Fatigue 2.0 (0, 5.0) 4.0 (2.0, 6.0) 0.008 1.0 (-0.3 to 2.0) 2.0 (0.7 to 3.4) 0.19 
   Emotion 3.1 (1.9 to 4.4) 5.3 (3.3 to 7.3) 0.07 0.5 (-3.0, 4.0) 2.0 (-1.0, 6.0) 0.12 
   Mastery 1.8 (1.0 to 2.7) 3.4 (2.1 to 4.7) 0.047 0.5 (-1.0, -3.0) 2.0 (-2.0, 5.0) 0.29 
   Total 11 (3.0, 20.0) 20 (8.0, 27.0) 0.008 3.0 (-8.0, 16.0) 10 (-2.0, 19.0) 0.07 
 
Data are mean (95%CI) or median (Q1, Q3). METs: Metabolic Equivalents; ISWT: 
Incremental Shuttle Walk Test; CRQ: Chronic Respiratory Questionnaire (The CRQ domain 
scores range from: dyspnea: 5 to 35; fatigue: 4 to 28; emotion: 7 to 49; mastery: 4 to 28.  
The total score of the CRQ-SA ranges from 20 to 140 with higher scores representing better 
health status) 
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TABLE 3. Baseline characteristics and change in primary and secondary outcome measures 
in the intervention and control groups restricted to participants not achieving ≥150 minutes 
of moderate intensity physical activity per week at baseline  
Data are mean (SD), mean (95%CI) or median (Q1, Q3). METs: Metabolic Equivalents; ISWT: 
Incremental Shuttle Walk Test; CRQ: Chronic Respiratory Questionnaire 
  
Variable Baseline (n=38) - 
 Intervention (n=19) Control (n=19) - 
Sex (male) (number 
(%)) 
14 (74) 14 (74) - 
Age (years) 70 (7) 69 (8) - 
FEV1 (% predicted) 49.1 (20.2) 47.1 (23.8) - 
FEV1/FVC 0.52 (0.16) 0.47 (0.18) - 
MRC score 3 (1) 4 (1) - 
BMI (kg/m
2
) 32.6 (7.8) 29.1 (3.8) - 
 
Change baseline to  
immediately following PR (n=38) 
Change baseline to  
6 months following PR (n=38) 
 
Intervention 
(n=19) 
Control 
(n=19) 
p 
value 
Intervention  
(n=19) 
Control 
(n=19) 
p 
value 
Primary outcome:   
Time ≥3 METs 
(minutes/day) 
10 (2 to 18) 10 (6 to 15) 0.20 2 (-1, 25) 14 (5, 31) 0.52 
Secondary outcomes: 
Accelerometer step 
count (steps/day) 
229 (131 to 588) 206 (186 to 599) 0.60 1 (-436, 655) -530 (-933, -292) 0.05 
Pedometer step count 
(steps/day) 
285 (-20, 779) 461 (35, 1170) 0.72 505 (-744, 1128) 258 (-243, 1236) 1.0 
ISWT distance 
(meters) 
32 (4 to 60) 46 (4 to 96) 0.59 10 (-25 to 45) -3 (-53 to 59) 0.82 
CRQ       
   Dyspnea 3.8 (-0.3 to 7.2) 6.0 (2.8 to 9.0) 0.34 0.9 (-2.0 to 3.9) 4.2 (-0.8 to 7.5) 0.09 
   Fatigue 2.2 (-0.2 to 4.3) 3.6 (1.8 to 5.4) 0.31 1.3 (-1.6 to 4.2) 1.8 (-1.3 to 4.9) 0.57 
   Emotion 3.5 (-0.3 to 6.7) 3.4 (0.1 to 6.9) 0.96 -2.2 (-9.6 to 5.2) 1.6 (-2.8 to 6.0) 0.27 
   Mastery 2.6 (-0.5 to 4.6) 2.7 (0.1 to 5.3) 0.94 -1.1 (-6.4 to 4.2) 0.7 (-2.3 to 3.7) 0.50 
   Total 
11.6 (3.6 to 
19.5) 
15.6 (6.7 to 
24.5) 
0.52 -1.1 (-16.6 to 14.5) 8.0 (-3.9 to 20.2) 0.23 
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FIGURES 
 
560 people with COPD were referred to Harefield PR Unit 
311 did not meet inclusion criteria 
65 home exercise program 
246 community PR sites not involved in the 
study 
94 declined to participate 
155 consented 
 
155 completed pre-PR assessment 
 
1 withdrawn due to nickel allergy 
2 withdrew from PR due to illness 
 
 
 
152 randomized 
 
 
 
76 assigned to pedometer and PR  
 
 
 
 
76 assigned to PR 
 
 
63 completed post-PR assessment 
46 with complete pre- and post-PR primary outcome data 
 
 
 
59 completed post-PR assessment 
46 with complete pre- and post-PR primary outcome data 
 
 
 
56 completed the 6 month assessment  
44 with complete pre- and 6 months post-PR primary 
outcome data 
 
57 completed the 6 month assessment 
49 with complete pre- and 6 months post-PR 
primary outcome data 
 
12 did not complete PR: 
8 unwell 
2 converted to a home 
exercise program  
1 returned to work 
1 unknown 
1 withdrawn due to mental health 
issues  
 
 
17 did not complete PR: 
10 unwell 
4 family commitments 
1 converted to a home 
exercise program  
1 alcohol problems 
1 unknown 
 
 
 
 
20 did not attend 6 month assessment: 
12 unable to contact 
3 unwell 
1 family commitments 
1 too much hassle 
1 unknown 
2 deaths 
 
 
 
 
19 did not attend 6 month 
assessment: 
13 unable to contact 
3 unwell 
1 unknown 
2 deaths 
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FIGURE 1: CONSORT diagram  
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FIGURE 2: Daily time spent ≥3 METs before, after and 6 months following PR in the control and 
intervention group  
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FIGURE 3:  Progression of daily pedometer step count targets during pulmonary rehabilitation among 
participants allocated to the intervention group. Horizontal lines show median (Q1, Q3) values 
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ONLINE SUPPLEMENT 
Pedometer step count targets during pulmonary rehabilitation in COPD: a randomized 
controlled trial 
 
Pulmonary Rehabilitation program 
Pulmonary rehabilitation (PR) was an 8-week outpatient exercise and multidisciplinary 
education program.  It was delivered according to the British Thoracic Society Quality 
Standards for PR (1) and comprised two supervised sessions of exercise and education, and at 
least one additional home-based exercise session per week. Each supervised session would 
last two hours (15 minutes warm up, 60 minutes supervised exercise, 45 minutes education).   
Respiratory physiotherapists supervised the exercise sessions which involved progressive, 
individually tailored aerobic and resistance training.  Initial walking speed was prescribed at 
80% of predicted peak oxygen consumption based on the Incremental Shuttle Walk test 
(ISW) performance (2) with the aim of patients exercising for 15 minutes continuously. 
Initial endurance cycling was set at a workload to achieve level 3 to 4 on the Borg Dyspnea 
Scale (3) with the aim of patients completing 15 minutes of continuous training. Lower limb 
resistance training was based on the American College of Sport’s Medicine resistance 
training guidelines (4) with an initial prescription of 2 sets of 10 seated leg press repetitions 
based on 60% of a one-repetition maximum, as well as sit-to-stand, knee extension, hip 
flexion and hip abduction exercises with appropriate free weights and ankle weights. Upper 
limb resistance training comprised biceps curls, shoulder press and upright row with free 
weights. Patients received an individualised, written home exercise program during PR and 
an individualised structured, written plan for on-going exercise maintenance on completion of 
PR. 
A multidisciplinary team, including physiotherapists, psychologists, dieticians, nurses, 
doctors, occupational therapists, dieticians, social workers, speech and language therapists 
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and expert patients, delivered the education sessions. They aimed to develop patients’ 
understanding and holistic management of their disease, and topics included physical activity 
and exercise, medication use, diet, smoking cessation, coping strategies, as well as managing 
infections through early recognition, rescue medication and appropriate general 
practice/hospital presentation. Patients received a booklet of the topics covered in these 
sessions. 
 
Further details on the intervention protocol 
The additional intervention was the provision of a pedometer (Yamax Digiwalker CW700®, 
Yamax, Nottingham, UK), an individualised daily step count target, and a step count diary 
provided during and for 6 months following PR. The first step count target was to increase 
the pedometer step count from the baseline pre-PR assessment by 5% over the forthcoming 
week (e.g. 250 additional steps from a baseline mean daily step count of 5,000). Participants 
were encouraged to achieve the prescribed target each day and to record the attained 
pedometer step count in their step count diary each evening.  The step count diary was a 
booklet listing the days of the week with a space beside each day for the participant to record 
the daily pedometer step count. Each week before their PR session, participants were 
reviewed by the trial coordinator, who was not involved in the PR program delivery, to 
prescribe a new daily step count target for the following week. The target was to achieve a 
5% increase in the preceding week’s average daily pedometer step count, as retrieved from 
the pedometer memory function. If the participant did not attend PR in person, the target was 
prescribed by telephone. At this weekly review, each patient was counselled on the 
importance of achieving the pedometer step count and was given advice on how to increase 
physical activity levels. The clinical team delivering the PR program were blinded to 
participants’ group allocation.  
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On completion of the PR program, participants in the intervention group received a final step 
count target and a 6 month step count diary. This target  was a 20% increase in step count 
from the baseline assessment. Participants were encouraged to achieve the prescribed target 
each day until the 6 month PR assessment and to record the attained pedometer step count in 
their step count diary each evening.  Participants were encouraged to achieve this target until 
the 6 month PR assessment. 
 
Physical activity measurement 
Participants wore an accelerometer (SenseWear®, Body Media Inc, Pittsburgh, USA) and 
pedometer for 7 days following the baseline, post-rehabilitation, and, 6 month follow-up 
assessment visits.  The accelerometer provides a valid, reliable, and, objective measure of 
physical activity in COPD (5). It is internationally recommended for use within intervention 
trials and data covering ≥22.5/24 hours for ≥5 days is advocated (6, 7). Mean daily step count 
and time spent performing moderate intensity physical activity (≥3 METs) was recorded (6-
8). The mean daily pedometer step count over 7 days was also recorded. The Yamax 
pedometer was chosen as it has been used in previous experimental and observational studies 
involving COPD subjects and has been identified as the most reliable and valid pedometer 
currently available (9-14).  Numerous studies have reported that it displays face and construct 
validity as well as inter-model reliability on flat ground at speeds above 2.5-3mph in healthy 
adults and COPD subjects (9, 11, 13, 15-17). However, the convergent validity is disputed 
due to inconsistent correlation with accelerometer-measured step count (16, 18)rec 
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RESULTS 
TABLE 1: Reasons for missing accelerometer data 
Time-point Intervention group Control group 
Pre-PR to post-PR  
 
46 / 76 matched pairs 46 / 76 matched pairs 
30 missing pairs: 
 12 did not complete PR 
 14 provided insufficient 
accelerometer data 
 2 declined to wear the 
accelerometer 
 1 withdrawn from the 
study 
 1 allergic reaction to the 
acclerometer 
30 missing pairs: 
 17 did not complete PR 
 12 provided insufficient 
accelerometer data 
 1 allergic reaction to the 
acclerometer 
 
Pre-PR to 6 month 
post-PR  
44 / 76 matched pairs  49 /76 matched pairs  
32 missing pairs: 
 20 did not attend the 6 
months post-PR assessment 
 8 provided insufficient 
accelerometer data 
 3 declined to wear the 
accelerometer 
 1 allergic reaction to the 
acclerometer 
27 missing pairs: 
 19 did not attend the 6 
month post-PR 
assessment 
 6 insufficient 
accelerometer data 
 2 allergic reaction to the 
acclerometer 
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TABLE 2: Baseline characteristics, change post-PR and change 6 months post-PR using complete cases 
 
Data are median (Q1, Q3). METs: Metabolic Equivalents; ISWT: Incremental Shuttle Walk Test. 
 
TABLE 3: Results of ANCOVA analysis adjusting for baseline CRQ values  
CRQ p value 
   Dyspnea 0.13 
   Fatigue 0.01 
   Emotion 0.40 
   Mastery 0.24 
   Total 0.04 
 
  
 Baseline characteristics 
Change baseline to 
immediately post-PR 
Change baseline to 6 months 
post-PR 
 
Total  
(n=134) 
Pedometer 
(n=64) 
Control 
(n=70) 
 
Pedometer 
(n=46) 
 
 
Control 
(n=46) 
 
p 
value 
 
Pedometer 
(n=44) 
 
 
Control 
(n=49) 
 
p 
value 
Primary outcome: 
Time ≥3 METs 
(minutes/day) 
46 (19, 85) 45 (20, 81) 47 (18, 103) 8 (-2, 36) 
12 (-4, 
36) 
0.71 2 (-29, 30) 6 (-16, 33) 0.70 
Secondary 
outcome: 
Accelerometer 
step count 
(steps/day) 
3323 (1654, 
5535) 
3293 (1717, 
5502) 
3456 (1567, 
5925) 
386 (-580, 
787) 
57 (-658, 
855) 
0.76 
-308 (-1009, 
269) 
-571 (-1848, 
187) 
0.41 
 n=151 n=76 n=75 n=58 n=55  n=47 n=51  
Pedometer step 
count (steps/day) 
2418 (1440, 
4261) 
2329 (1416, 
4449) 
2531 (1440, 
4062) 
534 (53, 
2152) 
179 (-
539, 
1189) 
0.06 
350 (-630, 
1434) 
-296 (-722, 
791) 
0.12 
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TABLE 4. Baseline characteristics and change in primary and secondary outcome measures in pedometer 
and control groups restricted to participants achieving ≥150 minutes of moderate intensity physical 
activity per week at baseline 
 
   
Variable Baseline (n=114)  
 
Pedometer 
(n=57) 
Control 
(n=57) 
 
Sex (male) (number 
(%)) 
42 (74) 40 (70)  
Age (years) 68 (10) 68 (8)  
FEV1 (% predicted) 51.1 (21.0) 51.4 (21.3)  
FEV1/FVC 0.50 (0.14) 0.51 (0.15)  
MRC score 3 (1) 3 (1)  
BMI (kg/m
2
) 27.4 (5.7) 27.1 (5.0)  
 
Change baseline to  
immediately following PR (n=114) 
Change baseline to  
6 months following PR (n=114) 
 
Pedometer 
(n=57) 
Control 
(n=57) 
p 
value 
Pedometer  
(n=38) 
Control 
(n=38) 
p 
value 
Primary outcome:   
Time ≥3 METs 
(minutes/day) 
10 (-2, 33) 10 (-3, 34) 0.85  2 (34, 27 )  12 (-16, 30)  0.45  
Secondary outcomes: 
Accelerometer step 
count (steps/day) 
452 (64 to 967) 167 (290 to 623) 0.84   -319 (-989, 108)  -422 (-1304, -53)  0.85 
Pedometer step count 
(steps/day) 
1093 (70, 2360) 52 (-768, 1237) 0.05   350 (-630, 1987)  -458 (-1509, 679)  0.13 
ISWT distance 
(meters) 
 69 (53 to 85) 73 (51 to 84)  0.33 39 (12 to 65)  36 (9, 63) 0.87 
CRQ           
   Dyspnea  3.6 (1.9 to 5.4) 5.5 (3.8 to 7.2)  0.13 2.1 (-0.1 to 4.3)  3.6 (1.7 to 5.4)  0.30 
   Fatigue 2.3 (1.3 to 3.4)  4.6 (3.2 to 3.0)  0.01 0.9 (-0.4 to 2.2)  2.1 (0.6 to 3.7)  0.24 
   Emotion 3.0 (1.7 to 4.3)  5.8 (3.4 to 8.3)  0.04 0.5 (-1.5 to 2.4)  3.2 (0.7 to 5.7)  0.9 
   Mastery 1.6 (0.6 to 2.5)  3.6 (2.1 to 5.1)  0.03 -0.5 (-1.9 to 0.9)  -0.4 (-1.8 to 1.0)  0.13 
   Total 
 10.5 (7.1 to 
14.0 
19.5 (13.6 to 
25.5) 
 0.01 -5.7 (-10.5 to -1.0) 
 -6.4 (-10.3 to -
2.5) 
 0.08 
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